Tablet Corvalol

General characteristics. Structure:

Active ingredients: acid a-bromizovalerianovoy ethyl ether, phenobarbital, mint oil;

1 tablet contains acid a-bromizovalerianovoy ethyl ether in terms of 100% substance of 12,42 mg, phenobarbital in terms of 100% dry matter of 11,34 mg, oils of mint of 0,88 mg;

excipients: lactoses monohydrate, magnesium stearate, β-cyclodextrin, potassium to atsesulfa.

Pharmacological properties:

Корвалол® – the calming and spasmolytic drug which effect is defined by the components which are its part.

Ethyl ether of α-bromizovalerianovy acid has the reflex calming and spasmolytic effect caused by irritation preferential of receptors of an oral cavity and a nasopharynx, decrease in reflex irritability in the central parts of the nervous system and strengthening of the phenomena of braking in neurons of bark and subcrustal structures of a brain and also decrease of the activity of the central vasomotor centers and direct local spasmolytic action on smooth muscles of vessels.

Phenobarbital suppresses the activating influences of the centers of a reticular formation of an average and a myelencephalon on bark of big hemispheres, thereby reducing flows of exciting influences on a cerebral cortex and subcrustal structures. Reduction of the activating influences renders, depending on a dose, the calming, tranquilizing or somnolent effect. Корвалол® reduces exciting influences on vasomotor centers, coronary and peripheral vessels, reducing the general arterial pressure, removing and warning vasospasms, especially cordial.

Oil of mint contains a large amount of essential oils, including about 50% of menthol and 4-9% of ethers of menthol. They are capable to irritate "cold" receptors of an oral cavity and to reflex expand preferential vessels of heart and brain, removing spasms of smooth muscles, to cause the calming and easy cholagogue action. Oil of a peppermint has antiseptic and spasmolytic action, has ability to eliminate the meteorism phenomena.

At reception sublingual absorption begins already in hypoglossal area, bioavailability of active agents high (about 60-80%). The effect is shown quickly (in 5-10 minutes). At intake action develops 15-45 minutes later and lasts for 3-6 hours. At persons who accepted drugs of barbituric acid earlier duration of action is reduced due to the accelerated metabolism of phenobarbital in a liver where barbiturates cause induction of enzymes. At people of advanced age and at patients with cirrhosis metabolism of Korvalola® is reduced therefore their elimination half-life is extended that demands reduction of a dose and lengthening of intervals between administrations of drug.

Indications to use:

Neurosises with an acrimony;
sleeplessness;
in complex therapy of an idiopathic hypertensia and vegeto-vascular dystonia;
unsharply expressed spasms of coronary vessels, tachycardia;
the enterospasms caused by neurovegetative frustration (as spasmolytic drug).

Route of administration and doses:

Корвалол® appoint sublingual (under language) or inside the adult on 1 tablet 2-3 times a day.

If necessary (the expressed tachycardia and a spasm of coronary vessels) the single dose can be increased to 3 tablets.

Duration of use of drug is determined by the doctor depending on clinical effect and portability of drug.

Features of use:

Use during pregnancy or feeding by a breast. Not to apply during pregnancy and during feeding by a breast.

Ability to influence speed of response at control of motor transport or work with other mechanisms. Drug should not be accepted to the persons working with mechanisms, to drivers of motor transport, etc.

Children. There is no experience of use for treatment of children.

Side effects:

Корвалол®, as a rule, it is well transferred. In some cases such side effects can be observed:

from the alimentary system: discomfort in a stomach and intestines, nausea;

from a nervous system: drowsiness, slight dizziness, decrease in concentration of attention;

from immune system: allergic reactions;

from cardiovascular system: delay of a cordial rhythm.

These phenomena are eliminated with reduction of a dose.

At prolonged use emergence of dependence on drug and the phenomena of a bromism is possible. Symptoms: oppression of the central nervous system, depression, apathy, rhinitis, conjunctivitis, acne, hemorrhagic diathesis, lack of coordination, confusion of consciousness.

Interaction with other medicines:

Drugs of the central oppressing type of action strengthen action of Korvalola®. Existence in composition of drug of phenobarbital can induce liver enzymes, and it does undesirable its simultaneous use with drugs which are metabolized in a liver (with coumarin derivatives, griseofulvin, glucocorticoids, peroral contraceptives) as their efficiency will decrease as a result of higher metabolic rate. Корвалол® strengthens action mestnoanesteziruyushchy, anesthetizing and hypnagogues, it is connected with the maintenance of derivatives of barbituric acid.

At simultaneous use with valproic acid its effect amplifies.

At simultaneous use with a methotrexate toxicity of the last amplifies.

Alcohol strengthens effect of drug, also increases its toxicity.

Contraindications:

Hypersensitivity to drug components, bromine;
the expressed abnormal liver functions and/or kidneys;
hepatic porphyria;
heavy heart failure.

Appropriate security measures at use

 

It is necessary to avoid the simultaneous use of alcoholic drinks.

Prolonged use of drug in connection with possible formation of dependence on drug is not recommended.

It is necessary to appoint carefully drug at arterial hypotension.

Overdose:

The overdose is possible at frequent or prolonged use of drug that it is connected with cumulation of its components. Prolonged and constant use can cause dependence, an abstinence syndrome, psychomotor excitement. The sharp termination of administration of drug can cause a withdrawal.

Overdose symptoms: oppression of the central nervous system, confusion of consciousness, dizziness, an ataxy, drowsiness, up to a deep sleep. In hard cases of poisoning – breath disturbance, tachycardia, arrhythmias, a lowering of arterial pressure, a collapse, a coma.

Symptomatic treatment.

Storage conditions:

Period of validity 2 years. Not to use drug after the termination of the period of validity specified on packaging. To store in the place protected from light at a temperature not over 25 ºС. To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

On 10 tablets in the blister. On 1, 3 or 5 blisters in a pack.